PCM
TOVX icon

Prelude Capital Management’s Theriva Biologics TOVX Stock Holding History

Prelude Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1
Closed -$11K – 1718
2017
Q3 		$11K Hold
1
– – ﹤0.01% 1421
2017
Q2 		$6K Buy
+1
New +$4.98K ﹤0.01% 1454
2016
Q3 		– Hold
0
– -$1K – 1822
2016
Q2 		– Hold
0
– – – 1533

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's TOVX Position: Q4 2017 in Review

Prelude Capital Management sold out of Theriva Biologics (TOVX) in Q4 2017, closing a stake of 1 share — an estimated $11K sold.

Prelude Capital Management first reported a position in TOVX in Q2 2017 and held it in 2 quarters. The position peaked at $11K in Q3 2017. 48 funds tracked by Wall St. Rank hold TOVX as of Q4 2017.

  • Prelude Capital Management reported no remaining Theriva Biologics position as of Q4 2017 after selling out during the quarter.
  • Prelude Capital Management sold 1 Theriva Biologics share in Q4 2017, an estimated $11K.
  • Prelude Capital Management first reported a position in Theriva Biologics in Q2 2017 and held it in 2 quarters.
  • Prelude Capital Management's Theriva Biologics position peaked at $11K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.